

Phylogica Appoints Renowned Pharmaceutical Executives as Non-Executive Directors

Perth, Australia, 18th April 2017: Phylogica Ltd (ASX:PYC) (Phylogica or the Company), a drug discovery company developing the next generation of intracellular biologic therapeutics, is pleased to announce the appointment today of Dr Robert Hayes and Dr Rick Kendall as Independent Non-Executive Directors of the Company, with immediate effect. Mr Jeremy Curnock Cook has taken this opportunity to retire from the Board.

Dr Robert Hayes

Dr Hayes was previously Head of Biologics at multinational biopharmaceutical company Amgen (NASDAQ:AMGN), responsible for the leadership, strategic direction and operational management of the company's biologics preclinical discovery and biotherapeutics pipeline. This included bioreagent generation, large molecule lead identification, biologics optimization, and the transition to upstream process development and manufacturing.

Prior to Amgen, Dr Hayes spent seven years as Vice President & Venture Leader of a biotech company within Janssen R&D that focused on developing and exploiting small alternative scaffold proteins. He was also a Senior Director of Protein Engineering at Johnson and Johnson, one of the worlds' largest healthcare companies, for over three years.

With over 20 years' experience in biotech start-ups and large pharmaceutical companies, Dr Hayes has a proven track record in building teams around new scientific ideas and technologies. He also has significant experience in forming partnerships between biotech companies and university partners to advance the development and application of novel therapeutic platforms.

Dr Hayes holds a Ph.D. from the Imperial College London, where he was the Royal College of Science Scholar and a Royal Society University Research Fellow. He also completed postdoctoral research at Imperial and University California at Berkeley.

Dr Hayes commented: *"I'm looking forward to joining the Phylogica board. Having worked with the company in a previous role, I was impressed by their drug discovery team. Since then, I've noticed the rapid progress they've made in validating the application of Phylomer technology for the more efficient intracellular delivery of biologics."*

Dr Rick Kendall

Based in California, Dr Kendall is currently Vice President Research at Kite Pharma, responsible for the company's research pipeline and developing CAR-T technology.

Previously, Dr Kendall was Executive Director of Oncology Research at Amgen, where he directed a group of 90+ scientists, and was responsible for the development of the Amgen cancer franchise strategy aligning research with other functions including Chemistry, Protein Sciences, Medical Translational Sciences, Development and Commercial. Results included 17 clinical candidate molecules made up of 9 small molecules and 8 protein therapeutics. Dr Kendall holds an associate adjunct professor position in the Department of Molecular, Cellular and Developmental Biology, at the University of California at Santa Barbara.

Dr Kendall has consulted to Phylogica in recent months on the development of the company's assets including the iMyc oncology program and Functional Penetrating Phylomer (FPP) intracellular drug delivery technology.

Dr Kendall has commented. *"I am pleased to join the Phylogica Board and contribute to the goal of developing Phylogica's innovative technology to target previously intractable targets important in cancer and other diseases with high unmet medical need."*

Mr Jeremy Curnock Cook

Mr Curnock Cook has been a Director of Phylogica since February 2012 and has made a valuable contribution to the Company's present position and capacity to focus on the development of cell penetrating Phylomers and oncology drug candidates. He is also the CEO of fund manager Bioscience Managers Ltd. Recent increases in activity of that company and its responsibilities has created limits upon his ability to continue with other activities. He has therefore taken this renewal of the Phylogica board as an opportunity to retire as a Director.

The Board of Phylogica would like to take this opportunity to thank Jeremy, on their own behalf and for shareholders, for his dedicated contribution to the Company.

Board Comment

Phylogica's Chief Scientific Advisor, **Professor Paul Watt** commented: *"We are delighted to secure two individuals of this calibre to join Phylogica's board."*

Dr Rob Hayes brings an extensive background in biologics discovery and preclinical development and a wealth of contacts at the highest level of large pharmaceutical companies, which will be of great assistance in the Company's business development activities.

Dr Rick Kendall is well-recognised as a leading global expert in Oncology drug development with an impressive track record of success. His advice has already resulted in enhancements of Phylogica’s program to further strengthen the demonstration of drug-like properties of the Company’s peptides.

Stephanie Unwin, Phylogica’s Chair, adds: *“We are delighted to have Dr Hayes and Dr Kendall joining the Phylogica board at this exciting time in the development of our oncology programs and intracellular delivery platform, and we look forward to benefiting from their extensive biologics drug development experience .”*

-ENDS-

For further information, please contact:

Investors	Media
Stephanie Unwin Chair E: stephanieu@phylogica.com M: 0411 132 287	Ben Walsh WE Buchan E: bwalsh@buchanwe.com.au M: 0411 520 012

About Phylogica

Phylogica Limited (ASX: PYC) is an oncology-focussed biotech company discovering and developing a new generation of biologics-based therapies against intracellular cancer targets. The company was originally spun out from the Telethon Kids Institute (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). Phylogica controls access to the world's most structurally diverse source of peptides - called Phylomers. The company specialises in Phylomer-based solutions to discover and deliver novel biologics drugs against intractable intracellular cancer targets with unprecedented potencies. Phylogica is advancing its proprietary oncology programmes developing first-in-class therapies against transcription factors such as Myc and Stat5. These targets play a critical role in many common cancers such as breast, lung, prostate and pancreatic, but have proven undruggable with conventional small molecule therapies. Within the last six years, the company has entered into discovery collaborations with Roche, Genentech, MedImmune, Pfizer, Janssen and Cubist Pharmaceuticals.